A revised view of cardiac sodium channel 'blockade' in the long-QT syndrome

Nicholas G. Kambouris, H. Bradley Nuss, David C. Johns, Eduardo Marbán, Gordon F. Tomaselli, Jeffrey R. Balser

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Mutations in SCN5A, encoding the cardiac sodium (Na) channel, are linked to a form of the congenital long-QT syndrome (LQT3) that provokes lethal ventricular arrhythmias. These autosomal dominant mutations disrupt Na channel function, inhibiting channel inactivation, thereby causing a sustained ionic current that delays cardiac repolarization. Sodium channel- blocking antiarrhythmics, such as lidocaine, potently inhibit this pathologic Na current (I(Na)) and are being evaluated in patients with LQT3. The mechanism underlying this effect is unknown, although high-affinity 'block' of the open Na channel pore has been proposed. Here we report that a recently identified LQT3 mutation (R1623Q) imparts unusual lidocaine sensitivity to the Na channel that is attributable to its altered functional behavior. Studies of lidocaine on individual R1623Q single-channel openings indicate that the open-time distribution is not changed, indicating the drug does not block the open pore as proposed previously. Rather, the mutant channels have a propensity to inactivate without ever opening ('closed-state inactivation'), and lidocaine augments this gating behavior. An allosteric gating model incorporating closed-state inactivation recapitulates the effects of lidocaine on pathologic I(Na). These findings explain the unusual drug sensitivity of R1623Q and provide a general and unanticipated mechanism for understanding how Na channel-blocking agents may suppress the pathologic, sustained Na current induced by LQT3 mutations.

Original languageEnglish (US)
Pages (from-to)1133-1140
Number of pages8
JournalJournal of Clinical Investigation
Volume105
Issue number8
DOIs
StatePublished - Jan 1 2000
Externally publishedYes

Fingerprint

Long QT Syndrome
Sodium Channels
Lidocaine
Mutation
Pharmaceutical Preparations
Cardiac Arrhythmias

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kambouris, N. G., Nuss, H. B., Johns, D. C., Marbán, E., Tomaselli, G. F., & Balser, J. R. (2000). A revised view of cardiac sodium channel 'blockade' in the long-QT syndrome. Journal of Clinical Investigation, 105(8), 1133-1140. https://doi.org/10.1172/JCI9212

A revised view of cardiac sodium channel 'blockade' in the long-QT syndrome. / Kambouris, Nicholas G.; Nuss, H. Bradley; Johns, David C.; Marbán, Eduardo; Tomaselli, Gordon F.; Balser, Jeffrey R.

In: Journal of Clinical Investigation, Vol. 105, No. 8, 01.01.2000, p. 1133-1140.

Research output: Contribution to journalArticle

Kambouris, NG, Nuss, HB, Johns, DC, Marbán, E, Tomaselli, GF & Balser, JR 2000, 'A revised view of cardiac sodium channel 'blockade' in the long-QT syndrome', Journal of Clinical Investigation, vol. 105, no. 8, pp. 1133-1140. https://doi.org/10.1172/JCI9212
Kambouris, Nicholas G. ; Nuss, H. Bradley ; Johns, David C. ; Marbán, Eduardo ; Tomaselli, Gordon F. ; Balser, Jeffrey R. / A revised view of cardiac sodium channel 'blockade' in the long-QT syndrome. In: Journal of Clinical Investigation. 2000 ; Vol. 105, No. 8. pp. 1133-1140.
@article{265e67af15c94aa399267c32db6b30b1,
title = "A revised view of cardiac sodium channel 'blockade' in the long-QT syndrome",
abstract = "Mutations in SCN5A, encoding the cardiac sodium (Na) channel, are linked to a form of the congenital long-QT syndrome (LQT3) that provokes lethal ventricular arrhythmias. These autosomal dominant mutations disrupt Na channel function, inhibiting channel inactivation, thereby causing a sustained ionic current that delays cardiac repolarization. Sodium channel- blocking antiarrhythmics, such as lidocaine, potently inhibit this pathologic Na current (I(Na)) and are being evaluated in patients with LQT3. The mechanism underlying this effect is unknown, although high-affinity 'block' of the open Na channel pore has been proposed. Here we report that a recently identified LQT3 mutation (R1623Q) imparts unusual lidocaine sensitivity to the Na channel that is attributable to its altered functional behavior. Studies of lidocaine on individual R1623Q single-channel openings indicate that the open-time distribution is not changed, indicating the drug does not block the open pore as proposed previously. Rather, the mutant channels have a propensity to inactivate without ever opening ('closed-state inactivation'), and lidocaine augments this gating behavior. An allosteric gating model incorporating closed-state inactivation recapitulates the effects of lidocaine on pathologic I(Na). These findings explain the unusual drug sensitivity of R1623Q and provide a general and unanticipated mechanism for understanding how Na channel-blocking agents may suppress the pathologic, sustained Na current induced by LQT3 mutations.",
author = "Kambouris, {Nicholas G.} and Nuss, {H. Bradley} and Johns, {David C.} and Eduardo Marb{\'a}n and Tomaselli, {Gordon F.} and Balser, {Jeffrey R.}",
year = "2000",
month = "1",
day = "1",
doi = "10.1172/JCI9212",
language = "English (US)",
volume = "105",
pages = "1133--1140",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "8",

}

TY - JOUR

T1 - A revised view of cardiac sodium channel 'blockade' in the long-QT syndrome

AU - Kambouris, Nicholas G.

AU - Nuss, H. Bradley

AU - Johns, David C.

AU - Marbán, Eduardo

AU - Tomaselli, Gordon F.

AU - Balser, Jeffrey R.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Mutations in SCN5A, encoding the cardiac sodium (Na) channel, are linked to a form of the congenital long-QT syndrome (LQT3) that provokes lethal ventricular arrhythmias. These autosomal dominant mutations disrupt Na channel function, inhibiting channel inactivation, thereby causing a sustained ionic current that delays cardiac repolarization. Sodium channel- blocking antiarrhythmics, such as lidocaine, potently inhibit this pathologic Na current (I(Na)) and are being evaluated in patients with LQT3. The mechanism underlying this effect is unknown, although high-affinity 'block' of the open Na channel pore has been proposed. Here we report that a recently identified LQT3 mutation (R1623Q) imparts unusual lidocaine sensitivity to the Na channel that is attributable to its altered functional behavior. Studies of lidocaine on individual R1623Q single-channel openings indicate that the open-time distribution is not changed, indicating the drug does not block the open pore as proposed previously. Rather, the mutant channels have a propensity to inactivate without ever opening ('closed-state inactivation'), and lidocaine augments this gating behavior. An allosteric gating model incorporating closed-state inactivation recapitulates the effects of lidocaine on pathologic I(Na). These findings explain the unusual drug sensitivity of R1623Q and provide a general and unanticipated mechanism for understanding how Na channel-blocking agents may suppress the pathologic, sustained Na current induced by LQT3 mutations.

AB - Mutations in SCN5A, encoding the cardiac sodium (Na) channel, are linked to a form of the congenital long-QT syndrome (LQT3) that provokes lethal ventricular arrhythmias. These autosomal dominant mutations disrupt Na channel function, inhibiting channel inactivation, thereby causing a sustained ionic current that delays cardiac repolarization. Sodium channel- blocking antiarrhythmics, such as lidocaine, potently inhibit this pathologic Na current (I(Na)) and are being evaluated in patients with LQT3. The mechanism underlying this effect is unknown, although high-affinity 'block' of the open Na channel pore has been proposed. Here we report that a recently identified LQT3 mutation (R1623Q) imparts unusual lidocaine sensitivity to the Na channel that is attributable to its altered functional behavior. Studies of lidocaine on individual R1623Q single-channel openings indicate that the open-time distribution is not changed, indicating the drug does not block the open pore as proposed previously. Rather, the mutant channels have a propensity to inactivate without ever opening ('closed-state inactivation'), and lidocaine augments this gating behavior. An allosteric gating model incorporating closed-state inactivation recapitulates the effects of lidocaine on pathologic I(Na). These findings explain the unusual drug sensitivity of R1623Q and provide a general and unanticipated mechanism for understanding how Na channel-blocking agents may suppress the pathologic, sustained Na current induced by LQT3 mutations.

UR - http://www.scopus.com/inward/record.url?scp=0034006834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034006834&partnerID=8YFLogxK

U2 - 10.1172/JCI9212

DO - 10.1172/JCI9212

M3 - Article

VL - 105

SP - 1133

EP - 1140

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 8

ER -